Novel approaches for the induction of T helper 1 (Th1)- or Th2-type mucosal and parenteral immune responses

Bibliography

• STAATS HF, JACKSON RJ, MARINARO M et al: Mucosal immunity to infection with implications for vaccine development. Curr. Opin. Immunol. (1994) 6(4):572–583.
   PubMed Web of Science ®Google Scholar
• McGHEE JR, MESTECKY J, DERTZBAUGH MT et al: The mucosal immune system: from fundamental concepts to vaccine development. Vaccine (1992) 10(2):75–88.
   PubMed Web of Science ®Google Scholar
• MESTECKY J, McGHEE JR : Immunoglobulin A (IgA): mo-lecular and cellular interactions involved in the IgA biosynthesis and immune response. Adv. Immunol (1987) 40:153–245.
   PubMed Web of Science ®Google Scholar
• MOSMANN TR, COFFMAN RL : Till and TH2 cells: differ-ent patterns of lymphokine secretion lead to different functional properties. Annu. Rev. Immunol. (1989) 7:145–173.
   PubMed Web of Science ®Google Scholar
• SALLUSTO F, MACKAY CR, LANZAVECCHIA A: Selective expression of the eotaxin receptor CCR3 by human T helper 2 cells. Science (1997) 277 (5334) :2005–2007.
   PubMed Web of Science ®Google Scholar
• •This paper and [8] demonstrate that Thl- and Th2-type cells possess different surface molecules that can mediate their differential trafficking.
   Google Scholar
• SALLUSTO F, LENIG D, MACKAY CR et al.: Flexible pro- grams of chemokine receptor expression on human polarized T helper 1 and 2 lymphocytes. J. Exp. Med. (1998) 187(6)875–883.
   Google Scholar
• BONECCHI R, BIANCHI G, BORDIGNON PP et al.: Differ-ential expression of chemokine receptors and chemo-tactic responsiveness of type 1 T helper cells (This) and Th2s. J. Exp. Med. (1998) 187(0:129–134.
   PubMedGoogle Scholar
• AUSTRUP F, VESTWEBER D, BORGES E et al.: P- and E-selectin mediate recruitment of T-helper-1 but not T-helper-2 cells into inflamed tissues. Nature (1997) 385(6610:81–83.
   PubMedGoogle Scholar
• •This paper and [5] demonstrate that Thl- and Th2-type cells possess different surface molecules that can mediate their differential trafficking.
   Google Scholar
• FINKELMAN FD, HOLMES J, KATONA IM et al.: Lym-phokine control of in vivo immunoglobulin isotype se-lection. Annu. Rev. Immunol. (1990) 8:303–333.
   PubMed Web of Science ®Google Scholar
• SEDER RA, PAUL WE: Acquisition of lymphokine-producing phenotype by CD4+ T cells. Annu. Rev. Im-munol. (1994) 12:635–673.
   PubMed Web of Science ®Google Scholar
• TRINCHIERI G: Interleukin-12: a pro-inflammatory cy-tokine with immunoregulatory functions that bridges innate resistance and antigen-specific adaptive immu-nity. Annu. Rev. Immunol. (1995) 13:251–276.
   PubMed Web of Science ®Google Scholar
• ROGGE L, BARBERIS-MAINO L, BIFFI M et al.: Selective expression of an interleukin-12 receptor component by human T helper 1 cells. J. Exp. Med. (1997) 185 (5):825–831.
   PubMed Web of Science ®Google Scholar
• •This paper identifies IL-12R on Thl-type cells.
   Google Scholar
• SZABO SJ, DIGHE AS, GUBLER U et al.: Regulation of the interleukin (IL)-12R beta 2 subunit expression in de-veloping T helper 1 (Thl) and Th2 cells. J. Exp. Med. (1997) 185(5):817–824.
   PubMed Web of Science ®Google Scholar
• •This paper indicates that IL-12R can regulate Thl/Th2 devel-opmental pathways.
   Google Scholar
• PFEIFFER C, STEIN J, SOUTHWOOD S et al.: Altered pep-tide ligands can control CD4 T lymphocyte differentia-tion in vivo. J. Exp. Merl. (1995) 181(4): 1569–1574.
   PubMed Web of Science ®Google Scholar
• KUMAR V, BHARDWAJ V, SOARES L et al.: Major histo-compatibility complex binding affinity of an antigenic determinant is crucial for the differential secretion of interleukin 4/5 or interferon gamma by T cells. Proc. Natl. Acad. Sci. USA (1995): 92(21):9510–9514.
   PubMed Web of Science ®Google Scholar
• HOSKEN NA, SHIBUYA K, HEATH AW et al.: The effect ofantigen dose on CD4 + T helper cell phenotype devel-opment in a T cell receptor-alpha beta-transgenic model. J. Exp. Merl. (1995) 182(5):1579–1584.
   PubMed Web of Science ®Google Scholar
• CONSTANTS, PFEIFFER C, WOODARD A et al.: Extent of Tcell receptor ligation can determine the functional dif-ferentiation of naive CD4 + T cells. J. Exp. Merl. (1995) 182(5):1591–1596.
   PubMed Web of Science ®Google Scholar
• SCHOUNTZ T, KASSELMAN JP, MARTINSON FA et al.: MHC genotype controls the capacity of ligand density to switch T helper (Th)-1/Th-2 priming in vivo. J. Immu-nol. (1996) 157(9):3893–3901.
   PubMed Web of Science ®Google Scholar
• FOWELL DJ, MAGRAM J, TURCK CW et al: Impaired Th2 subset development in the absence of CD4. Immunity (1997) 6(5)559–569.
   Google Scholar
• KUCHROO VK, DAS MP, BROWN JA et al: B7-1 and B7-2 costimulatory molecules activate differentially the Thl/Th2 developmental pathways: application to autoimmune disease therapy. Cell (1995) 80(5)707–718.
   Google Scholar
• ••A study demonstrating that B7–1 and B7-2 molecules can in-fluence the Thl/Th2 developmental pathways.
   Google Scholar
• WEINER HL: Oral tolerance: immune mechanisms and treatment of autoimmune diseases. Immunol. Today (1997) 18(7):335–343.
   PubMedGoogle Scholar
• SPANGLER BD: Structure and function of cholera toxinand the related Escherichia coil' heat-labile entero-toxin. Microbic)]. Rev. (1992) 56(4):622–647.
   PubMedGoogle Scholar
• DOUCE G, TURCOTTE C, CROPLEY I et al: Mutants ofEscherichia coil' heat-labile toxin lacking ADP-ribosyltransferase activity act as nontoxic, mucosal adjuvants. Proc. Natl. Acad. Sci. USA (1995) 92 (5):1644–1648.
   PubMed Web of Science ®Google Scholar
• DI TOMMASO A, SALETTI G, PIZZA M et al. Induction of antigen-specific antibodies in vaginal secretions using a nontoxic mutant of LT as a mucosal adjuvant. Infect. Immun. (1996) 64(3):974–979.
   PubMed Web of Science ®Google Scholar
• GIULIANI MM, DEL GIUDICE G, GIANNELLI V etal. Muco- sal adjuvanticity and immunogenicity of LTR72, a novel mutant of Escherichia coli heat-labile entero-toxin with partial knockout of the ADP- ribosyltransferase activity. J. Exp. Merl. (1998) 187(7):1123–1132.
   PubMed Web of Science ®Google Scholar
• DOUCE G, FONTANA M, PIZZA M eta].:Intranasal immu- nogenicity and adjuvanticity of site-directed mutant derivatives of cholera toxin. Infect. Immun. (1997) 65(7) 2821–2828
   Google Scholar
• YAMAMOTO S, TAKEDA Y, YAMAMOTO M eta].:Mutants in the ADP-ribosyltransferase cleft of cholera toxin lack diarrheagenicity but retain adjuvanticity. J. Exp. Med. (1997) 185(7):1203–1210.
   Google Scholar
• MOSMANN TR, SAD S: The expanding universe of T-cellsubsets: Thl, Th2 and more. Immunol Today (1996) 17(3):138–146.
   PubMedGoogle Scholar
• ABBAS AK, MURPHY KM, SHER A: Functional diversityof helper T lymphocytes. Nature (1996) 383(6603):787–793.
   PubMed Web of Science ®Google Scholar
• ROMAGNANI S: The Thl/Th2 paradigm. Immunol. To-day (1997) 18(6):263–266.
   PubMedGoogle Scholar
• ROLLWAGEN FM, BAQAR S: Oral cytokine administra-tion. Immunol. Today (1996) 17(12):548–550.
   PubMedGoogle Scholar
• MARINARO M, BOYAKA PN, FINKELMAN FD et al: Oralbut not parenteral interleukin 00-12 redirects T helper 2 (Th2)-type responses to an oral vaccine with-out altering mucosal IgA responses. J. Exp. Merl. (1997) 185 (3):415–427.
   PubMed Web of Science ®Google Scholar
• DONNELLY JJ, ULMER JB, SHIVER JW et al.: DNA vaccines. Annu. Rev. Immunol. (1997) 15:617–648.
   PubMed Web of Science ®Google Scholar
• ROBINSON HL, TORRES CA: DNA vaccines. Semin. Immu-nol. (1997) 9(5):271–283.
   PubMedGoogle Scholar
• PERTMER TM, ROBERTS TR, HAYNES JR: Influenza virus nucleoprotein-specific immunoglobulin G subclass and cytokine responses elicited by DNA vaccination are dependent on the route of vector DNA delivery. J. Virol. (1996) 70(9):6119–6125.
   PubMed Web of Science ®Google Scholar
• FELTQUATE DM, HEANEY S, WEBSTER RG et al.: Differ-ent T helper cell types and antibody isotypes gener-ated by saline and gene gun DNA immunization. J. Immunol. (1997) 158(5):2278–2284.
   PubMed Web of Science ®Google Scholar
• •This paper demonstrates that different routes or methods of DNA administration result in predominant Thl- or Th2-type immune responses.
   Google Scholar
• RAZE, TIGHE H, SATO Y et al: Preferential induction of a Thl immune response and inhibition of specific IgE antibody formation by plasmid DNA immunization. Proc. Natl. Acad. Sci. USA (1996) 93(10):5141–5145.
   PubMed Web of Science ®Google Scholar
• •A study showing that immunisation with plasmid DNA can prevent IgE responses.
   Google Scholar
• HSU CH, CHUA KY, TAO MH et al.: Immunoprophylaxis of allergen-induced immunoglobulin E synthesis and airway hyperresponsiveness in vivo by genetic immu-nization. Nat. Med. (1996) 2(5):540–544.
   PubMed Web of Science ®Google Scholar
• •A report describing that genetic immunisation can down-regulate pre-existing IgE responses.
   Google Scholar
• XIANG ZQ, ERTL HCJ: Manipulation of the immune re- sponse to a plasmid-encoded viral antigen by coinocu-lation with plasmids expressing cytokines. Immunity (1995) 2(2):129–135.
   PubMed Web of Science ®Google Scholar
• •This paper demonstrates that immune responses to plasmid-encoded antigens can be effectively modulated by co-administration of plasmid-encoded cytokines.
   Google Scholar
• CONRY RM, WIDERA G, LOBUGLIO AF et al.: Selected strategies to augment polynucleotide immunization. Gene Ther. (1996) 3 (0 :67–74.
   PubMedGoogle Scholar
• PASQUINI S, XIANG Z, WANG Y et al.: Cytokines and costimulatory molecules as genetic adjuvants. Immu-nol. Cell. Biol. (1997) 75(4):397–401.
   PubMed Web of Science ®Google Scholar
• OKADA E, SASAKI S, ISHII N et al.: Intranasal immuniza-tion of a DNA vaccine with IL-12- and granulocyte-macrophage colony-stimulating factor (GM-CSF)-e-xpressing plasmids in liposomes induces strong mu-cosal and cell-mediated immune responses against 11IV-1 antigens. J. Immunol. (1997) 159(7):3638–3647.
   PubMed Web of Science ®Google Scholar
• KIM JJ, BAGARAZZI ML, TRIVEDI N et al.: Engineering of in vivo immune responses to DNA immunization via codelivery of costimulatory molecule genes. Nat. Bio-technol (1997) 15(7):641–646.
   PubMedGoogle Scholar
• CURTISS R III, KELLY SM, TINGE SA et al.: Recombinant Salmonella vectors in vaccine development. Dev. Stand. (1994) 82:23–33.
   PubMedGoogle Scholar
• CHATFIELD S, ROBERTS M, LI J et al.: The use of live at-tenuated Salmonella for oral vaccination. Dev. Stand. (1994) 82:35–42.
   PubMedGoogle Scholar
• DARR A, GUZMAN CA, GERSTEL B et al.: Oral somatic transgene vaccination using attenuated S. ty-phimurium. Cell (1997) 91 (6) :765–775.
   Google Scholar
• ••This paper together with [49] demonstrates that recombinantbacterial vectors can be used to deliver plasmid DNA to the host.
   Google Scholar
• DIETRICH G, BUBERT A, GENTSCHEV I et al.: Delivery of antigen-encoding plasmid DNA into the cytosol of macrophages by attenuated suicide Listeria monocy-togenes. Nat. Biotechnol. (1998) 16(2):181–185.
   PubMed Web of Science ®Google Scholar
• COURVALIN P, GOUSSARD S, COURVALIN CG: Gene transfer from bacteria to mammalian cells. CR Acad. Sci. (Paris) (1995) 318:1207–1212.
   PubMed Web of Science ®Google Scholar
• SIZEMORE DR, BRANSTROM AA, SADOFF JC: Attenuated Shigella as a DNA delivery vehicle for DNA-mediated immunization. Science (1995) 270(5234):299–302.
   PubMed Web of Science ®Google Scholar
• ••This paper together with [46] demonstrates that recombinantbacterial vectors can be effectively used to deliver plasmid DNA to the host.
   Google Scholar
• KRIEG AM, YI A-K, MATSON S et al.: CpG motifs in bacte- rial DNA trigger direct B cell activation. Nature (1995) 374(6522)546–549.
   Google Scholar
• •This paper identifies immunostimulatory sequences in bac-terial DNA.
   Google Scholar
• KLINMAN DM, YI A-K, BEAUCAGE SL et al. CpG motifs present in bacterial DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon y. Proc. Natl. Acad. Sci. USA (1996) 93(7):2879–2883.
   PubMed Web of Science ®Google Scholar
• SATO Y, ROMAN M, TIGHE H et al.: ImmunostimulatoryDNA sequences necessary for effective intradermal gene immunization. Science (1996) 273(5273):352–354.
   PubMed Web of Science ®Google Scholar
• PISETSKY DS: Immune activation by bacterial DNA: anew genetic code. Immunity (1996) 5(4):303–310.
   PubMed Web of Science ®Google Scholar
• COWDERY JS, CHACE JH, YI A-K et al. Bacterial DNA in- duces NK cells to produce IFN-y in vivo and increases the toxicity of lipopolysaccharides. j Immunol. (1996) 156(12) 4570–4575
   PubMed Web of Science ®Google Scholar
• HALPERN MD, KURLANDER RJ, PISETSKY DS: BacterialDNA induces murine interferon-y production by stimulation of interleukin-12 and tumor necrosis fac-tor-a. Cell. Immunol. (1996) i67(1):72–78.
   Google Scholar
• ROMAN M, MARTIN-OROZCO E, GOODMAN JS et al.: Im-munostimulatory DNA sequences function as T helper- 1-promoting adjuvant. Nature Med. (1997) 3 (8):849–854.
   PubMed Web of Science ®Google Scholar
• •A report describing the ability of immunostimulatory DNA sequences to trigger Thl-type immune responses.
   Google Scholar
• CHU RS, TARGONI OS, KRIEG AM et al.: CpG oligode-oxynucleotides act as adjuvants that switch on T helper 1 (Thl) immunity. J. Exp. Med. (1997) 186(101623–1631.
   Google Scholar
• SPARWASSER T, MIETHKE T, LIPFORD G et al.: BacterialDNA causes septic shock. Nature (1997) 386(6623)336–337.
   Google Scholar
• THANAVALA Y, YANG YF, LYONS P et al.: Immunogenic-ity of transgenic plant-derived hepatitis B surface anti-gen. Proc. Natl. Acad. Sci. USA (1995) 92 (8):3358–3361.
   PubMed Web of Science ®Google Scholar
• •A report showing that transgenic tobacco plants can be used to produce antigens with intact B- and T-cell epitopes.
   Google Scholar
• ARNTZEN CJ, MASON HS: Oral vaccine production inthe edible tissues of transgenic plants. In: New Genera-tion Vaccines. Levine MM, Woodrow GC, Kaper JB, Cobon GS (Eds.), Marcel Dekker, Inc., New York (1996):263–277.
   Google Scholar
• HAQ TA, MASON HS, CLEMENTS JD et al: Oral immuniza-tion with a recombinant bacterial antigen produced in transgenic plants. Science (1995) 268(5211):714–716.
   PubMed Web of Science ®Google Scholar
• ••A study showing that antigens expressed by transgenic po-tato and tobacco plants can be effectively used to orally im-munise mice.
   Google Scholar
• MASON HS, BALL JM, SHI JJ et al. Expression of Norwalk virus capsid protein in transgenic tobacco and potato and its oral immunogenicity in mice. Proc. Natl. Acad. Sci. USA (1996) 93(11):5335–5340.
   PubMed Web of Science ®Google Scholar
• ARAKAWA T, CHONG DKX, LANGRIDGE WHR: Efficacy of a food plant-based oral cholera toxin B subunit vac-cine. Nat. Biotechnol. (1998) 16(3):292–297.
   PubMed Web of Science ®Google Scholar
• TACKET CO, MASON HS, LOSONSKY G et al.: Immuno- genicity in humans of a recombinant bacterial antigen delivered in a transgenic potato. Nat. Med. (1998) 4 (5):607–609.
   PubMed Web of Science ®Google Scholar
• ••This report presents results from a clinical trial in which atransgenic potato was employed to orally immunise humans.
   Google Scholar
• MAY GD, AFZA R, MASON HS et al.: Generation of trans-genic banana (Musa acuminata) plants via Agrobacte-rium-mediated transformation. Bio/7'echnology (1995) 13:486–492.
   Google Scholar
• CLENDENNEN SK, MAY GD: Differential gene expres-sion in ripening banana fruit. Plant Physiol (1997) 115 (2):463–469.
   PubMed Web of Science ®Google Scholar